Redeye strengthens its positive view of Formpipe following the Q4 report.
Alisa Bank’s H2 was in line with our expectations on profitability while growth was more constrained...
Redeye shares its preview of BONESUPPORT’s Q4 2024 results, due February 25.
Redeye expects strong performance from the Lifecare division in Q4 2024, though weaker results from ...
För det kommande året tror Analysguiden på ytterligare några räntesänkningar, vilket kommer att få e...
ESL Shipping segment reported clean EBITA of EUR 4.
Redeye returns with a more in-depth take on Sedana Medical’s Q4 report.
Redeye updates on Embracer following Q3-results where the company saw solid performance in PC/Consol...
Doro delivered another report with solid gross and operating margins.
Redeye provides an update on AcouSort following its year-end report, which did not include any surpr...
Redeye argues that BeammWave has shifted to a new phase with three customers representing most of th...
Redeye states that Acconeer’s Q4 2024 report was mixed, with a slight net sales miss, while EBITDA w...
Redeye updates its Base Case and forecasts following Fortnox’s Q4 report, with sales and EBIT matchi...
Minor estimate revisions Swedish operations could fund future international growth Maintain fair val...
Sales better than expected, adj. EBITDA in line We leave our estimates relatively unchanged Still po...
6% organic sales decline y-o-y Finnish market is seeing signs of improvement Adj.
Redeye strengthens its positive view of CombinedX following a solid Q4 considering the soft market.
2024 closed with record sales, EBIT and order intake Increased TAM assumptions prompt upgrades, EBIT...
On February 14, 2025, Nosa Plugs published the company’s interim report for the fourth quarter of 20...
Redeye remains confident that Powercell is on a solid growth track.